Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025
Edgewise Therapeutics (NASDAQ: EWTX), a muscle disease biopharmaceutical company, has announced its upcoming participation in the RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for Tuesday, May 20, 2025, at 9:00 am ET. The event will feature a live webcast accessible through the company's Events & Presentations page, with replay availability for a limited time after the conference. Attendees are advised to connect several minutes before the start time to ensure proper connection.
Edgewise Therapeutics (NASDAQ: EWTX), un'azienda biofarmaceutica specializzata nelle malattie muscolari, ha annunciato la sua partecipazione al RBC Capital Markets Global Healthcare Conference. La presentazione 猫 prevista per marted矛 20 maggio 2025 alle 9:00 ET. L'evento sar脿 trasmesso in diretta streaming, accessibile tramite la pagina Eventi e Presentazioni della societ脿, con la possibilit脿 di rivedere la registrazione per un periodo limitato dopo la conferenza. Si consiglia ai partecipanti di collegarsi qualche minuto prima dell'inizio per assicurarsi una connessione stabile.
Edgewise Therapeutics (NASDAQ: EWTX), una compa帽铆a biofarmac茅utica especializada en enfermedades musculares, ha anunciado su pr贸xima participaci贸n en la RBC Capital Markets Global Healthcare Conference. La presentaci贸n est谩 programada para el martes 20 de mayo de 2025 a las 9:00 am ET. El evento contar谩 con una transmisi贸n en vivo accesible a trav茅s de la p谩gina de Eventos y Presentaciones de la empresa, con disponibilidad de repetici贸n por un tiempo limitado despu茅s de la conferencia. Se recomienda a los asistentes conectarse varios minutos antes del inicio para asegurar una conexi贸n adecuada.
Edgewise Therapeutics (NASDAQ: EWTX)電� 攴检湣 歆堩櫂 氚旍澊鞓れ牅鞎� 須岇偓搿�, RBC Capital Markets Global Healthcare Conference鞐� 彀胳棳頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟. 氚滍憸電� 2025雲� 5鞗� 20鞚� 頇旍殧鞚� 鞓れ爠 9鞁�(霃欕秬鞁滉皠)鞐� 鞓堨爼霅橃柎 鞛堨姷雼堧嫟. 鞚� 頄夓偓電� 須岇偓鞚� 鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴 韼橃澊歆�毳� 韱淀暣 鞁れ嫓臧� 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌, 須岇潣 膦呺 頉� 鞝滍暅霅� 旮瓣皠 霃欖晥 雼れ嫓氤搓赴 靹滊箘鞀る弰 鞝滉车霅╇媹雼�. 彀胳劃鞛愲摛鞚� 鞗愴櫆頃� 鞝戩啀鞚� 鞙勴暣 鞁滌瀾 鞁滉皠 氇� 攵� 鞝勳棎 鞝戩啀頃� 瓴冹潉 甓岇灔頃╇媹雼�.
Edgewise Therapeutics (NASDAQ : EWTX), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les maladies musculaires, a annonc茅 sa prochaine participation 脿 la RBC Capital Markets Global Healthcare Conference. La pr茅sentation est pr茅vue pour le mardi 20 mai 2025 脿 9h00 ET. L'茅v茅nement sera diffus茅 en direct via la page 脡v茅nements et Pr茅sentations de la soci茅t茅, avec une rediffusion disponible pendant une dur茅e limit茅e apr猫s la conf茅rence. Il est conseill茅 aux participants de se connecter quelques minutes avant le d茅but afin d'assurer une connexion optimale.
Edgewise Therapeutics (NASDAQ: EWTX), ein biopharmazeutisches Unternehmen f眉r Muskelerkrankungen, hat seine bevorstehende Teilnahme an der RBC Capital Markets Global Healthcare Conference angek眉ndigt. Die Pr盲sentation ist f眉r Dienstag, den 20. Mai 2025, um 9:00 Uhr ET geplant. Die Veranstaltung wird als Live-Webcast 眉ber die Seite f眉r Veranstaltungen und Pr盲sentationen des Unternehmens zug盲nglich sein, mit einer begrenzten Zeitspanne f眉r die Wiedergabe nach der Konferenz. Den Teilnehmern wird empfohlen, sich einige Minuten vor Beginn einzuw盲hlen, um eine stabile Verbindung sicherzustellen.
- None.
- None.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise 聽and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to:聽聽or follow us on聽,听聽,听听补苍诲听.
View original content to download multimedia:
SOURCE Edgewise Therapeutics
FAQ
When is Edgewise Therapeutics (EWTX) presenting at the RBC Capital Markets Healthcare Conference?
How can investors access Edgewise Therapeutics' (EWTX) RBC Conference presentation?
What type of company is Edgewise Therapeutics (EWTX)?
Where can I find the webcast link for EWTX's RBC Conference presentation?
